胰腺癌的分子亚型：一种蛋白质组学方法。
Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach.
机构信息
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska.
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.
出版信息
Clin Cancer Res. 2021 Jun 15;27(12):3272-3274. doi: 10.1158/1078-0432.CCR-21-0640. Epub 2021 Apr 14.
Abstract
Through molecular subtyping, therapeutic vulnerabilities can be exploited for developing personalized medicine. The real utility of molecular subtyping lies in the clinical translation for disease characterization. Proteomic methods with defined marker sets hold great promise for improving therapy outcomes by improving the speed of predictions for devising treatment strategies..
摘要
通过分子亚型分类，可以利用治疗弱点来开发个性化药物。分子亚型分类的实际应用在于为疾病特征提供临床转化。具有明确标志物集的蛋白质组学方法有望通过提高制定治疗策略的预测速度来改善治疗效果。
相似文献
1
Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach.胰腺癌的分子亚型：一种蛋白质组学方法。
Clin Cancer Res. 2021 Jun 15;27(12):3272-3274. doi: 10.1158/1078-0432.CCR-21-0640. Epub 2021 Apr 14.
2
Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer.代谢分型用于新型个体化胰腺癌治疗。
Clin Cancer Res. 2020 Jan 1;26(1):6-8. doi: 10.1158/1078-0432.CCR-19-2926. Epub 2019 Oct 18.
3
Toward the goal of personalized therapy in pancreatic cancer by targeting the molecular phenotype.针对胰腺癌的分子表型靶向治疗以实现个体化治疗的目标。
Adv Exp Med Biol. 2013;779:91-143. doi: 10.1007/978-1-4614-6176-0_5.
4
Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.胰腺癌分子分型的治疗意义
Oncology (Williston Park). 2017 Mar 15;31(3):159-66, 168.
5
Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma.综合多组学分析确定了胰腺导管腺癌的新型分子亚型。
Genes Dis. 2023 Oct 14;11(6):101143. doi: 10.1016/j.gendis.2023.101143. eCollection 2024 Nov.
6
Subtyping for pancreatic cancer precision therapy.胰腺癌精准治疗的亚型分类
Trends Pharmacol Sci. 2022 Jun;43(6):482-494. doi: 10.1016/j.tips.2022.03.005. Epub 2022 Apr 7.
7
Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy.胰腺癌的个性化医疗：预后及对治疗的潜在影响。
J Gastrointest Surg. 2012 Sep;16(9):1651-2. doi: 10.1007/s11605-012-1943-1. Epub 2012 Jun 29.
8
Pharmacogenetics and Personalized Medicine in Pancreatic Cancer.胰腺癌中的药物遗传学与个性化医疗
Acta Med Iran. 2017 Mar;55(3):194-199.
9
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.对 1200 例胰腺导管腺癌的基因表达谱分析揭示了新的亚型。
BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8.
10
Newer Trends in Pancreatic Cancer Treatment: Genetic Alterations and the Role of Immune Therapeutic and Targeted Therapies.胰腺癌治疗的新趋势：基因改变以及免疫治疗和靶向治疗的作用。
Crit Rev Oncog. 2019;24(2):157-177. doi: 10.1615/CritRevOncog.2019031642.
引用本文的文献
1
Tumor Organoids Grown in Mixed-Composition Hydrogels Recapitulate the Plasticity of Pancreatic Cancers.在混合成分水凝胶中培养的肿瘤类器官重现了胰腺癌的可塑性。
Gels. 2025 Jul 21;11(7):562. doi: 10.3390/gels11070562.
2
MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways.巨噬细胞迁移抑制因子/核受体亚家族3成员C2轴通过丝裂原活化蛋白激酶-细胞外信号调节激酶和活化蛋白-1信号通路调控胰腺癌中的葡萄糖代谢重编程。
Carcinogenesis. 2024 Aug 12;45(8):582-594. doi: 10.1093/carcin/bgae025.
3
IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma.IMUP和GPRC5A：胰腺导管腺癌中两个新发现的风险评分指标。
Cancer Cell Int. 2021 Nov 24;21(1):620. doi: 10.1186/s12935-021-02324-w.
本文引用的文献
1
A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry.一种使用多重反应监测-质谱技术对胰腺导管腺癌进行风险亚组分类的临床适用的 24 蛋白模型。
Clin Cancer Res. 2021 Jun 15;27(12):3370-3382. doi: 10.1158/1078-0432.CCR-20-3513. Epub 2021 Feb 16.
2
Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer.代谢分型用于新型个体化胰腺癌治疗。
Clin Cancer Res. 2020 Jan 1;26(1):6-8. doi: 10.1158/1078-0432.CCR-19-2926. Epub 2019 Oct 18.
3
Molecular subtypes of pancreatic cancer.胰腺癌的分子亚型。
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. doi: 10.1038/s41575-019-0109-y.
4
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.基于肿瘤和微环境特征的胰腺导管腺癌分层。
Gastroenterology. 2018 Dec;155(6):1999-2013.e3. doi: 10.1053/j.gastro.2018.08.033. Epub 2018 Aug 27.
5
Molecular subtyping of cancer: current status and moving toward clinical applications.癌症的分子分型：现状与向临床应用的推进。
Brief Bioinform. 2019 Mar 25;20(2):572-584. doi: 10.1093/bib/bby026.
6
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.MUC1与HIF-1α信号转导相互作用诱导合成代谢性葡萄糖代谢，赋予胰腺癌吉西他滨耐药性。
Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004.
7
Genomic analyses identify molecular subtypes of pancreatic cancer.基因组分析确定了胰腺癌的分子亚型。
Nature. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.
8
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.虚拟显微切割鉴定出胰腺导管腺癌不同的肿瘤特异性和基质特异性亚型。
Nat Genet. 2015 Oct;47(10):1168-78. doi: 10.1038/ng.3398. Epub 2015 Sep 7.
Zotero 插件